Asian Conference on Clinical Pharmacy, Best Poster Presenter,Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched StudyHaruna Matsuzaki Masakazu Hatano Miko Iwata Shigeki Yamada
Taro Kishi Kenji Sakuma Masakazu Hatano Takenori Okumura Masaki Kato Hajime Baba Nakao Iwata
Neuropsychopharmacology reports 2024年2月
AIM: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials of available anti...
Journal of psychiatric research 167 132-138 2023年10月
The benefits of serotonin 3 receptor antagonists (5-HT3R-As) in obsessive-compulsive disorder (OCD) treatment remain unclear. Thus, this study aimed to perform a systematic review and a random-effects meta-analysis, including double-blind, randomi...
Miko Iwata Masakazu Hatano Kana Ito Haruna Matsuzaki Shigeki Yamada
Neuropsychiatric disease and treatment 19 2061-2068 2023年10月
PURPOSE: Several nationwide population-based studies have reported that patients with psychiatric disorders are at higher risk of developing chronic kidney disease, chronic liver disease, and metabolic syndrome than the general population; however...
BACKGROUND: Clozapine is the only antipsychotic medication with proven efficacy against treatment-resistant schizophrenia. This multicenter retrospective cohort study aimed to evaluate the impact of a delay in clozapine initiation on long-term out...
双極性障害は躁病エピソードやうつ病エピソードに代表される急性期と急性期症状が改善し臨床的に安定した維持期に大別される。最新のメタ解析研究では,各病期に対して様々な薬物治療の使用が提案されているが,薬物の種類に加え,それら薬物の用量にも着目した診療が重要である。本稿では,2017年に発表されたThe International College of Neuro-Psychopharmacology(CINP)Treatment Guidelines for Bipolar Disorder ...
お知らせ・マニュアル
医学部